Clinical Trials in Midlothian, Virginia
70 recruiting
Showing 1–20 of 60 trials
Recruiting
Phase 3
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Early Breast Cancer
Novartis Pharmaceuticals1,400 enrolled207 locationsNCT05827081
Recruiting
Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma+3 more
National Cancer Institute (NCI)1,210 enrolled1151 locationsNCT04267848
Recruiting
Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled283 locationsNCT06966700
Recruiting
Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Anatomic Stage II Breast Cancer AJCC v8Early Stage Breast CarcinomaAnatomic Stage I Breast Cancer AJCC v8
Alliance for Clinical Trials in Oncology1,524 enrolled631 locationsNCT06876714
Recruiting
Phase 2
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Stage I Bladder Cancer AJCC v8Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
National Cancer Institute (NCI)160 enrolled125 locationsNCT06770582
Recruiting
Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Breast Cancer (Early Breast Cancer)
AstraZeneca4,300 enrolled711 locationsNCT05774951
Recruiting
Phase 3
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Renal Cell Carcinoma (RCC)Clear Cell Renal Cell CarcinomaStage II Renal Pelvis Cancer AJCC v8+1 more
Alliance for Clinical Trials in Oncology1,040 enrolled410 locationsNCT06661720
Recruiting
Phase 3
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Stage IV Colorectal Cancer AJCC v8Metastatic Colorectal Adenocarcinoma
Alliance for Clinical Trials in Oncology364 enrolled183 locationsNCT05673148
Recruiting
Phase 3
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+1 more
Alliance for Clinical Trials in Oncology1,295 enrolled836 locationsNCT05812807
Recruiting
Phase 2
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Alliance for Clinical Trials in Oncology474 enrolled105 locationsNCT06632977
Recruiting
Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
National Cancer Institute (NCI)3,680 enrolled536 locationsNCT06058377
Recruiting
Phase 2Phase 3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma AJCC v7Muscle Invasive Renal Pelvis Urothelial Carcinoma+4 more
National Cancer Institute (NCI)992 enrolled494 locationsNCT05987241
Recruiting
Phase 3
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Breast Cancer
NRG Oncology3,960 enrolled1238 locationsNCT05879926
Recruiting
Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Stage III Prostate Cancer AJCC v8Prostate AdenocarcinomaStage IVA Prostate Cancer AJCC v8
NRG Oncology1,209 enrolled398 locationsNCT05946213
Recruiting
Phase 2Phase 3
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Stage III Colon Cancer
NRG Oncology1,912 enrolled1056 locationsNCT05174169
Recruiting
Phase 3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
Stage III Prostate Cancer AJCC v8Prostate AdenocarcinomaStage I Prostate Cancer AJCC v8+2 more
NRG Oncology586 enrolled347 locationsNCT04134260
Recruiting
Phase 3
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
AstraZeneca582 enrolled166 locationsNCT06350097
Recruiting
Phase 3
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
Malignant Solid Neoplasm
SWOG Cancer Research Network777 enrolled36 locationsNCT05642611
Recruiting
Not Applicable
Mobile Health for Adherence in Breast Cancer Patients
Breast CarcinomaHER2-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8+1 more
ECOG-ACRIN Cancer Research Group410 enrolled400 locationsNCT06112613
Recruiting
Not Applicable
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
Malignant Solid Neoplasm
ECOG-ACRIN Cancer Research Group760 enrolled181 locationsNCT06295367